Header Logo

Connection

CHARLES WYKOFF to Ranibizumab

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Ranibizumab.
CHARLES WYKOFF
Connection Strength
10.408
Ranibizumab
  1. Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis. Can J Ophthalmol. 2023 06; 58(3):252-261.
    View in: PubMed
    Score: 0.743
  2. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2021 Jun; 27(6):743-752.
    View in: PubMed
    Score: 0.717
  3. Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. Ophthalmol Retina. 2021 03; 5(3):224-233.
    View in: PubMed
    Score: 0.664
  4. Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial. Ophthalmic Surg Lasers Imaging Retina. 2018 04 01; 49(4):258-264.
    View in: PubMed
    Score: 0.576
  5. Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol. 2018 04; 102(4):460-464.
    View in: PubMed
    Score: 0.550
  6. Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. Am J Ophthalmol. 2017 Aug; 180:8-17.
    View in: PubMed
    Score: 0.543
  7. Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial. Ophthalmology. 2017 06; 124(6):919-921.
    View in: PubMed
    Score: 0.536
  8. Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials. Ophthalmology. 2016 08; 123(8):1716-1721.
    View in: PubMed
    Score: 0.506
  9. Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. Ophthalmology. 2015 Dec; 122(12):2514-22.
    View in: PubMed
    Score: 0.484
  10. Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis. Ophthalmol Retina. 2024 Mar; 8(3):223-233.
    View in: PubMed
    Score: 0.211
  11. Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023 06; 8(1).
    View in: PubMed
    Score: 0.206
  12. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM. Retina. 2023 03 01; 43(3):506-513.
    View in: PubMed
    Score: 0.202
  13. A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2023 06; 130(6):588-597.
    View in: PubMed
    Score: 0.201
  14. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials. Eye (Lond). 2023 07; 37(10):1966-1974.
    View in: PubMed
    Score: 0.198
  15. Frequency and timing of antivascular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context. BMJ Open Ophthalmol. 2022 08; 7(1).
    View in: PubMed
    Score: 0.194
  16. Refill-Exchange Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Trial Experience. Ophthalmic Surg Lasers Imaging Retina. 2022 05; 53(5):257-265.
    View in: PubMed
    Score: 0.191
  17. The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis. Ophthalmology. 2022 05; 129(5):498-508.
    View in: PubMed
    Score: 0.186
  18. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2021 02; 105(2):253-257.
    View in: PubMed
    Score: 0.166
  19. Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes. Ophthalmic Surg Lasers Imaging Retina. 2019 09 01; 50(9):e250-e256.
    View in: PubMed
    Score: 0.159
  20. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial. Ophthalmology. 2019 08; 126(8):1155-1170.
    View in: PubMed
    Score: 0.154
  21. Re: Adrean et?al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053). Ophthalmology. 2019 03; 126(3):e18-e19.
    View in: PubMed
    Score: 0.153
  22. Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes. Am J Ophthalmol. 2019 06; 202:91-99.
    View in: PubMed
    Score: 0.153
  23. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. Am J Ophthalmol. 2018 08; 192:84-90.
    View in: PubMed
    Score: 0.145
  24. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema. Ophthalmology. 2018 08; 125(8):1304-1306.
    View in: PubMed
    Score: 0.145
  25. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. J Manag Care Spec Pharm. 2018 Feb; 24(2-a Suppl):S3-S15.
    View in: PubMed
    Score: 0.142
  26. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial. Graefes Arch Clin Exp Ophthalmol. 2018 Mar; 256(3):511-518.
    View in: PubMed
    Score: 0.142
  27. The Intersection of Diabetes Mellitus and Cataract Surgery: Current State of Management. Ophthalmol Retina. 2018 02; 2(2):83-85.
    View in: PubMed
    Score: 0.141
  28. Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy. Curr Opin Ophthalmol. 2017 May; 28(3):213-218.
    View in: PubMed
    Score: 0.135
  29. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2017 02; 124(2):215-223.
    View in: PubMed
    Score: 0.131
  30. Randomized Trial of Treat and Extend Ranibizumab with and without Navigated Laser for Diabetic Macular Edema: TREX-DME 1 Year Outcomes. Ophthalmology. 2017 01; 124(1):74-81.
    View in: PubMed
    Score: 0.131
  31. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2016 Apr 01; 47(4):308-12.
    View in: PubMed
    Score: 0.125
  32. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Ophthalmic Surg Lasers Imaging Retina. 2015 Mar; 46(3):302-5.
    View in: PubMed
    Score: 0.116
  33. Progressive retinal nonperfusion in ischemic central retinal vein occlusion. Retina. 2015 Jan; 35(1):43-7.
    View in: PubMed
    Score: 0.115
  34. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul; 98(7):951-5.
    View in: PubMed
    Score: 0.108
  35. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology. 2013 Sep; 120(9):1945-6.e1.
    View in: PubMed
    Score: 0.105
  36. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr; 44(2):121-6.
    View in: PubMed
    Score: 0.101
  37. Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
    View in: PubMed
    Score: 0.056
  38. Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study. Lancet. 2024 04 20; 403(10436):1563-1573.
    View in: PubMed
    Score: 0.054
  39. Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: A meta-analysis of randomised trials. Acta Ophthalmol. 2024 Feb; 102(1):e31-e41.
    View in: PubMed
    Score: 0.051
  40. Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. Ophthalmology. 2023 Jul; 130(7):735-747.
    View in: PubMed
    Score: 0.051
  41. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes. Surv Ophthalmol. 2022 Sep-Oct; 67(5):1346-1363.
    View in: PubMed
    Score: 0.048
  42. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond). 2023 01; 37(1):6-16.
    View in: PubMed
    Score: 0.048
  43. Baseline retinal vascular bed area on ultra-wide field fluorescein angiography correlates with the anatomical outcome of diabetic macular oedema to ranibizumab therapy: two-year analysis of the DAVE Study. Eye (Lond). 2023 03; 37(4):678-683.
    View in: PubMed
    Score: 0.047
  44. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta Ophthalmol. 2022 Sep; 100(6):e1199-e1208.
    View in: PubMed
    Score: 0.046
  45. Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data. Am J Ophthalmol. 2022 04; 236:12-19.
    View in: PubMed
    Score: 0.046
  46. Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy. Br J Ophthalmol. 2023 03; 107(3):399-405.
    View in: PubMed
    Score: 0.046
  47. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Ophthalmology. 2020 09; 127(9):1179-1188.
    View in: PubMed
    Score: 0.041
  48. Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography. Am J Ophthalmol. 2020 01; 209:99-106.
    View in: PubMed
    Score: 0.040
  49. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. Eye (Lond). 2020 03; 34(3):480-490.
    View in: PubMed
    Score: 0.039
  50. Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion. Invest Ophthalmol Vis Sci. 2018 07 02; 59(8):3278-3285.
    View in: PubMed
    Score: 0.037
  51. Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study. Br J Ophthalmol. 2018 08; 102(8):1066-1071.
    View in: PubMed
    Score: 0.036
  52. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema. Ophthalmology. 2018 07; 125(7):1054-1063.
    View in: PubMed
    Score: 0.036
  53. Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. Ophthalmology. 2018 05; 125(5):683-690.
    View in: PubMed
    Score: 0.035
  54. Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study. Am J Ophthalmol. 2017 Aug; 180:110-116.
    View in: PubMed
    Score: 0.034
  55. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Can J Ophthalmol. 2015 Oct; 50(5):373-7.
    View in: PubMed
    Score: 0.030
  56. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina. 2014 Sep; 34(9):1728-35.
    View in: PubMed
    Score: 0.028
  57. Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology. 2014 Dec; 121(12):2432-42.
    View in: PubMed
    Score: 0.028
  58. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology. 2014 Sep; 121(9):1783-9.
    View in: PubMed
    Score: 0.027
  59. Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity. Retina. 2014 Jan; 34(1):48-54.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.